New Generation Gepants: Migraine Acute and Preventive Medications

Research output: Contribution to journalArticlepeer-review

37 Citations (Scopus)
157 Downloads (Pure)


Migraine is a debilitating disease whose clinical and social impact is out of debate. Tolera-bility issues, interactions, contraindications, and inefficacy of the available medications make new options necessary. The calcitonin-gene-related peptide (CGRP) pathway has shown its importance in migraine pathophysiology and specific medications targeting this have become available. The first-generation CGRP receptor antagonists or gepants, have undergone clinical trials but their development was stopped because of hepatotoxicity. The new generation of gepants, however, are efficacious, safe, and well tolerated as per recent clinical trials. This led to the FDA-approval of rimegepant, ubrogepant, and atogepant. The clinical trials of the available gepants and some of the newer CGRP-antagonists are reviewed in this article.

Original languageEnglish
Article number1656
JournalJournal of Clinical Medicine
Issue number6
Early online date16 Mar 2022
Publication statusPublished - 16 Mar 2022


  • Acute medications
  • CGRP
  • Gepants
  • Migraine
  • Painkillers


Dive into the research topics of 'New Generation Gepants: Migraine Acute and Preventive Medications'. Together they form a unique fingerprint.

Cite this